Provided by Tiger Fintech (Singapore) Pte. Ltd.

OKYO Pharma Limited

1.36
-0.2025-12.94%
Post-market: 1.36-0.0075-0.55%16:05 EDT
Volume:50.96K
Turnover:73.40K
Market Cap:46.24M
PE:-4.24
High:1.60
Open:1.60
Low:1.31
Close:1.57
Loading ...

Company Profile

Company Name:
OKYO Pharma Limited
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
3
Office Location:
14/15 Conduit St,Floor 4,London,Greater London,United Kingdom
Zip Code:
W1S 2XJ
Fax:
- -
Introduction:
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Directors

Name
Position
Gabriele Cerrone
Non-Executive Chairman
Bernard Denoyer
Non-Executive Director
Gary S. Jacob
CEO and Executive Director
John Brancaccio
Non-Executive Director
Willy Simon
Senior Non-Executive Director

Shareholders

Name
Position
Keeren Shah
Chief Financial Officer
Gary S. Jacob
CEO and Executive Director
Raj Patil
Chief Scientific Officer